In this phase I clinical trial, 2 different cohorts of patients with acute GVHD received subcutaneous injections of uhCG along with standard-of-care treatment.
Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.
This study separately evaluated the impact of depression/antidepressant use on the QOL and OS of cohorts of patients undergoing allogeneic or autologous HSCT.
First-line treatment of early-stage, unfavorable classic Hodgkin lymphoma with nivolumab plus doxorubicin, vinblastine, and dacarbazine resulted in high response rates and PFS in a phase 2 study.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.